Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Critical Limb Ischemia Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 18 Dec 17

The "Critical Limb Ischemia - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Critical Limb Ischemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 13, 4, 1 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Critical Limb Ischemia - Overview
  3. Critical Limb Ischemia - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Critical Limb Ischemia - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Critical Limb Ischemia - Companies Involved in Therapeutics Development
  • AnGes MG Inc
  • apceth Biopharma GmbH
  • Athersys Inc
  • BiogenCell Ltd
  • Caladrius Biosciences Inc
  • Cynata Therapeutics Ltd
  • Hemostemix Inc
  • Histocell SL
  • ID Pharma Co Ltd
  • Integene International Holdings LLC
  • Juventas Therapeutics Inc
  • Kang Stem Biotech Co Ltd
  • Kasiak Research Pvt Ltd
  • Neurofx Inc
  • Nissan Chemical Industries Ltd
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • ReNeuron Group Plc
  • Symic Biomedical Inc
  • TikoMed AB
  • U.S. Stem Cell Inc
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd

For more information about this report visit

View source version on

Business Wire

Last updated on: 18/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.